Therapeutic Vaccines: The Global Market
The total worldwide market for therapeutic vaccines is expected to reach $137 million in 2010. With increased product introductions, this market is expected to reach nearly $3.1 billion in 2014, a compound annual growth rate (CAGR) of nearly 118%.
The worldwide market for therapeutic cancer vaccines was worth $137 million in 2010. This market is expected to increase at a compound annual growth rate of 115% to reach an estimated $2.9 billion in 2014.
Addiction treatments are expected after 2012. These therapeutic vaccines are forecast to be worth $77 million in 2013 and $135 million in 2014, a compound annual growth rate (CAGR) of more than 100%.
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to BCC’s industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
Frequently Asked Questions (FAQs)
The total worldwide market for therapeutic vaccines was $8.1 million in 2004. With increased product introductions, this market is expected to top $4 billion in 2010.
Currently, only products for the treatment of cancer are available.
Addiction treatments are expected after 2005, but cancer treatments will continue to dominate.
The market and growth for these vaccines will mimic that of innovative prescription pharmaceuticals rather than prophylactic vaccines.
It is expected the U.S. will be the primary market. Europe will follow closely behind and Japan, while historically a very small market for prophylactic vaccines, is expected to be a major purchaser.